We are live on ! Find out more
AMAG

AMAG Pharmaceuticals
AMAG

Delisted

AMAG was delisted on the 13th of November, 2020.

154 hedge funds and large institutions have $1.36B invested in AMAG Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 38 increasing their positions, 47 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

509% more call options, than puts

Call options by funds: $914K | Put options by funds: $150K

440% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 10

75% more funds holding in top 10

Funds holding in top 10: 47 (+3)

61% more capital invested

Capital invested by funds: $847M → $1.36B (+$515M)

36% more funds holding

Funds holding: 113154 (+41)

19% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 47

Holders
154
Holders Change
+41
Holders Change %
+36.28%
% of All Funds
4.11%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.19%
New
54
Increased
38
Reduced
47
Closed
10
Calls
$914K
Puts
$150K
Net Calls
+$764K
Net Calls Change
+$626K
Name Holding Trade Value Shares
Change
Change in
Stake
HI
126
Horizon Investments
North Carolina
$365K
Tudor Investment Corp
127
Tudor Investment Corp
Connecticut
$359K +$305K +8,431 New
Jacobs Levy Equity Management
128
Jacobs Levy Equity Management
New Jersey
$349K +$296K +8,200 New
TI
129
Trexquant Investment
Connecticut
$334K +$283K +7,844 New
Bank of America
130
Bank of America
North Carolina
$322K +$245K +6,782 +889%
KCM
131
Kennedy Capital Management
Missouri
$314K -$530K -14,678 -67%
GCP
132
GSA Capital Partners
United Kingdom
$294K +$249K +6,896 New
LI
133
LMCG Investments
Massachusetts
$283K +$240K +6,646 New
UBS AM
134
UBS AM
Illinois
$268K
Principal Financial Group
135
Principal Financial Group
Iowa
$257K +$218K +6,037 New
TRCT
136
Tower Research Capital (TRC)
New York
$223K +$76.9K +2,129 +68%
BG
137
BlackRock Group
United Kingdom
$222K -$25.9K -718 -12%
SG Americas Securities
138
SG Americas Securities
New York
$213K +$181K +5,007 New
Legal & General Group
139
Legal & General Group
United Kingdom
$175K -$12K -332 -8%
Lazard Asset Management
140
Lazard Asset Management
New York
$159K +$62K +1,715 +85%
QT
141
Quantbot Technologies
New York
$136K +$105K +2,911 +987%
Citadel Advisors
142
Citadel Advisors
Florida
$65K -$715K -19,800 -93%
CSS
143
Cubist Systematic Strategies
Connecticut
$64K +$54.2K +1,500 New
Canada Life
144
Canada Life
Manitoba, Canada
$62K -$83.1K -2,300 -61%
SFU
145
Stonehage Fleming (UK)
United Kingdom
$38K +$31.9K +882 New
BlackRock
146
BlackRock
New York
$29K -$1.37K -38 -5%
Teacher Retirement System of Texas
147
Teacher Retirement System of Texas
Texas
$24K -$3.76K -104 -16%
LTFS
148
Ladenburg Thalmann Financial Services
Florida
$7K +$5.06K +140 +933%
CCS
149
Crosspoint Capital Strategies
California
$6K +$4.99K +138 New
GI
150
Gradient Investments
Minnesota
$4K

AMAG Hedge Fund Activity: Q4 2014 in Review

154 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q4 2014, worth a combined $1.36B — up 61% from $847M a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new AMAG positions and 10 closed out — a net gain of 44 holders — while 38 added to existing stakes and 47 trimmed.

The largest buyer was Wells Fargo, adding an estimated $35.6M. The largest seller was Visium Asset Management, exiting entirely with an estimated $60.3M sold.

  • 154 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q4 2014, up from 113 in Q3 2014.
  • Funds reported $1.36B of AMAG Pharmaceuticals stock for Q4 2014, up 61% quarter-over-quarter.
  • 54 funds opened new AMAG Pharmaceuticals positions in Q4 2014 and 10 closed out, a net change of +44 holders.
  • The largest AMAG Pharmaceuticals buyer in Q4 2014 was Wells Fargo, an estimated $35.6M added.
  • The largest AMAG Pharmaceuticals seller in Q4 2014 was Visium Asset Management, an estimated $60.3M sold.

Based on aggregated 13F filings for Q4 2014.